TrialSafety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
Trial details
- Registry ID
- NCT04533022
- Phase
- Phase 2
VCRE
Vicore Pharma AB
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPFNCT04533022 | Vicore Pharma AB | Phase 2 | Completed | 2024-03-30Actual |
| A Trial to Investigate Recovery From COVID-19 With C21 in Adult SubjectsNCT04880642 | Vicore Pharma AB | Phase 3 | Completed | 2022-04-25Actual |
| A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.NCT06588686 | Vicore Pharma AB | Phase 2 | Active not recruiting | 2027-05Estimated |
A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
Trial details
- Registry ID
- NCT04880642
- Phase
- Phase 3
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Trial details
- Registry ID
- NCT06588686
- Phase
- Phase 2
Latest recorded trial changes
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686 · Vicore Pharma AB
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
360 participants (planned)
+ After
378 participants (actual)
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686 · Vicore Pharma AB
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686 · Vicore Pharma AB
Primary completion date changed
− Before
Feb 2027
+ After
May 2027
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686 · Vicore Pharma AB
Planned enrollment increased by 90 participants
− Before
270 participants (planned)
+ After
360 participants (planned)